TVB-2640

TVB-2640 is an oral, selective fatty acid synthase (FASN) inhibitor. It reduces hepatic de novo lipogenesis in males with metabolic abnormalities. It is being evaluated in phase 2 clinical trials to treat KRAS mutant non-small cell lung carcinomas.